Cargando…
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer
In non‐small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive biomarker for patients treated with ICIs. Here, we evaluated the predictive power of TMB measured by the Oncomine™ Tumor M...
Autores principales: | Alborelli, Ilaria, Leonards, Katharina, Rothschild, Sacha I, Leuenberger, Laura P, Savic Prince, Spasenija, Mertz, Kirsten D, Poechtrager, Severin, Buess, Martin, Zippelius, Alfred, Läubli, Heinz, Haegele, Jasmin, Tolnay, Markus, Bubendorf, Lukas, Quagliata, Luca, Jermann, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972587/ https://www.ncbi.nlm.nih.gov/pubmed/31471895 http://dx.doi.org/10.1002/path.5344 |
Ejemplares similares
-
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
por: Ortega Sanchez, Guacimara, et al.
Publicado: (2018) -
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study
por: Alborelli, Ilaria, et al.
Publicado: (2019) -
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
por: König, David, et al.
Publicado: (2021) -
Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine
por: Ruiz, Christian, et al.
Publicado: (2016) -
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
por: Koelzer, Viktor H., et al.
Publicado: (2016)